Following a major new announcement from the company yesterday the RushNet Inc (OTCMKTS:RSHN) stock could come on to the radars of investors this morning and it may be a good move to perhaps take a look at the announcement.
On Wednesday, RSHN stock decreased 6.67% to $0.0014 with more than 11.12 million shares traded, compared to volume of 10.27 million shares. The stock moved within a range of $0.0014 – 0.0017 after opening trading at $0.0014.
Rushnet, Inc’s Subsidiary, heliosDX To Launch Wellness Patches for General Well-Being
The company announced yesterday that heliosDX, its subsidiary unit was one the verge of concluding the set up necessary for the manufacturing of a new range of wellness product. The product in question is a wellness patch and would be distributed in the United States in 2023. The announcement about a new product is almost always seen as a major positive by investors and it is going to be interesting to see if the stock comes into focus among investors today.
It was further noted that the wellness and CBD infused patches were going to be rolled out in the coming months by heliosDX. The products in question were going to take care of a wide range of problems starting from nausea and anxiety to low energy and sleeplessness. The company would first launch as many as 8 patches and following that the number of patches could be eventually expanded to 12. The company is going to use proprietary formulas for manufacturing the patches.
When CEO of heliosDX, Ashley Sweat, was asked about his thoughts of new ideas for this coming year to bolster the company’s bottom-line, he responded, “We are continuously searching for innovative ideas to bring to market which add value to patients, physicians and consumers. We believe our new patch line can produce significant volumes for a healthy-sized supplemental revenue stream. We see a large opportunity with this product line which provides a healthy alternative to traditional oral aids and supplements.” heliosDX COO, Yann Gerville-Reache added, “Most of the wellness products in the market today are consumed through a pill, lozenge, shakes or a gummy – all being metabolized via the digestive tract, which, for some, may cause gastric issues, and the intended benefit may be wasted altogether because it is not effectively absorbed.”